SUPREFACT DEPOT 3 MONTHS 9.45 MG
BUSERELIN (BUSERELIN ACETATE) : 9.45 MG · DIN 02240749 · CHEPLAPHARM ARZNEIMITTEL GMBH
Health Canada status: DORMANT
What is SUPREFACT DEPOT 3 MONTHS?
SUPREFACT DEPOT 3 MONTHS 9.45 MG contains BUSERELIN (BUSERELIN ACETATE) : 9.45 MG. It is listed in the Health Canada Drug Product Database under DIN 02240749, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as IMPLANT for SUBCUTANEOUS administration. Health Canada currently lists it as dormant, status dated 13-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SUPREFACT DEPOT 3 MONTHS used for?
SUPREFACT DEPOT 2 months and SUPREFACT DEPOT 3 months are indicated for the palliative treatment of patients with hormone-dependent advanced carcinoma of the prostate gland (Stage D).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is SUPREFACT DEPOT 3 MONTHS called?
The same molecule, BUSERELIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Receptal | Latin | Iceland |
| SUPREFACT OLDATOS INJEKCIÓ | Latin | Hungary |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02240749 |
|---|---|
| Brand name | SUPREFACT DEPOT 3 MONTHS |
| Generic / active ingredient | BUSERELIN (BUSERELIN ACETATE) : 9.45 MG |
| Manufacturer | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Strength | 9.45 MG |
| Dosage form | IMPLANT |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L02AE01 BUSERELIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 13-Oct-2024 |
| Original market date | 2000-02-24 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02240749 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2240749 |
| Brand name | SUPREFACT DEPOT 3 MONTHS |
| Active ingredient / INN | BUSERELIN (BUSERELIN ACETATE) : 9.45 MG |
| ATC code | L02AE01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L02 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
How is it stored and handled?
Store the intact package between 15 °C-30 °C. PROTECT FROM EXCESSIVE HEAT and do not use beyond the expiration date printed on the container label.
How is it supplied?
SUPREFACT DEPOT 2 months or SUPREFACT DEPOT 3 months is packaged in a sterile ready-to-use disposable applicator with an integrated safety engineered needle (internal needle diameter of 1.4 mm) for subcutaneous injection. Each carton is supplied with one sterile foil bag containing one applicator pre-filled with one implant dose SUPREFACT DEPOT 2 months consists of two identical rods, while SUPREFACT DEPOT 3 months consists of three identical rods.
Which pack is which?
| Strength on the label | 9.45 MG |
|---|---|
| Dosage form | IMPLANT |
| Route | SUBCUTANEOUS |
| Packaging as described in the monograph | SUPREFACT DEPOT 2 months or SUPREFACT DEPOT 3 months is packaged in a sterile ready-to-use disposable applicator with an integrated safety engineered needle (internal needle diameter of 1.4 mm) for subcutaneous injection. Each carton is supplied with one sterile foil bag containing one applicator pre-filled with one implant dose SUPREFACT DEPOT 2 months consists of two identical rods, while SUPREFACT DEPOT 3 months consists of three identical rods. |
| Storage | Store the intact package between 15 °C-30 °C. PROTECT FROM EXCESSIVE HEAT and do not use beyond the expiration date printed on the container label. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code L02AE01 BUSERELIN. 1 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SUPREFACT | 1 MG | SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 02225166 |
| SUPREFACT | 100 MCG | SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | CANCELLED POST MARKET | DIN 02225158 |
| SUPREFACT DEPOT 2 MONTHS | 6.3 MG | IMPLANT | CHEPLAPHARM ARZNEIMITTEL GMBH | DORMANT | DIN 02228955 |
| SUPREFACT INJ 1MG/ML | 1 MG | LIQUID | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00680028 |
| SUPREFACT INTRANASAL SOLUTION 1MG/ML | 1 MG | SPRAY | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00680036 |
| SUPREFACT LIQ 1MG/ML | 1 MG | LIQUID | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 01989669 |
Who else supplies BUSERELIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUSERELIN appears in 10 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BUSERELIN cost around the world?
BUSERELIN is listed on 5 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 4 | 4 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.